| Autor: |
Padilha WSC; Department of Nephrology, Hospital DFStar Rede D'Or São Luiz, Brasília, DF, Brazil., Cesar BN; Department of Nephrology, Hospital DFStar Rede D'Or São Luiz, Brasília, DF, Brazil., Pacheco ST; Department of Oncology, Hospital DFStar Rede D'Or São Luiz, Brasília, DF, Brazil., De Sousa AA; Department of Nephrology, Hospital DFStar Rede D'Or São Luiz, Brasília, DF, Brazil., Ledesma FL; Department of Pathology, University of Sao Paulo, São Paulo, SP, Brazil., Malheiros DMAC; Department of Pathology, University of Sao Paulo, São Paulo, SP, Brazil., Teixeira MCA; Department of Oncology, Hospital DFStar Rede D'Or São Luiz, Brasília, DF, Brazil. |
| Abstrakt: |
BACKGROUND Bevacizumab is an approved targeted therapy for metastatic cancer treatment. It can have adverse effects on multiple organs. Despite its low incidence, thrombotic microangiopathy (TMA) is the most severe complication. TMA has been associated with complement dysregulation, and treatment with eculizumab can be effective, despite the paucity of literature on eculizumab therapy for bevacizumab-associated TMA. To date, 10 cases have been reported, with less than half of them including a kidney biopsy. We present a new case of bevacizumab-associated TMA successfully treated with eculizumab, along with kidney biopsy records and an overview of mechanisms underlying TMA development in bevacizumab-treated patients. CASE REPORT A female patient diagnosed with metastatic breast cancer who was treated with bevacizumab in conjunction with chemotherapy was admitted to the hospital for acute kidney injury requiring hemodialysis, microangiopathic hemolytic anemia, and thrombocytopenia. TMA was diagnosed and was later confirmed by a kidney biopsy. Primary causes for TMA, such as ADAMTS13 deficiency and shiga toxin associated hemolytic-uremic syndrome, were ruled out, and the patient's condition was ultimately found to be triggered by exposure to bevacizumab. After discontinuing bevacizumab and receiving 4 weekly doses of eculizumab, kidney function and hematological parameters improved. CONCLUSIONS Bevacizumab-associated TMA can be reversed or attenuated in some patients with the use of eculizumab (inhibiting complement system overactivation), possibly reducing time to recovery, with fewer long-term sequelae. This additional case encourages future clinical trials to evaluate the safety and efficacy of eculizumab in cases of TMA associated with bevacizumab. |
